Similar articles

• Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease.

  Marti-Aguado D, Calleja JL, Vilar-Gomez E, Iruzubieta P, Rodríguez-Duque JC, Del Barrio M, Puchades L, Rivera-Esteban J, Perelló C, Puente A, Gomez-Medina C, Escudero-García D, Serra MA, Bataller R, Crespo J, Arias-Loste MT. Marti-Aguado D, et al. J Hepatol. 2024 Dec;81(6):930-940. doi: 10.1016/j.jhep.2024.06.036. Epub 2024 Jul 4. J Hepatol. 2024. PMID: 38971533
• ALT levels, alcohol use, and metabolic risk factors have prognostic relevance for liver-related outcomes in the general population.

  Männistö V, Salomaa V, Jula A, Lundqvist A, Männistö S, Perola M, Åberg F. Männistö V, et al. JHEP Rep. 2024 Jul 24;6(10):101172. doi: 10.1016/j.jhepr.2024.101172. eCollection 2024 Oct. JHEP Rep. 2024. PMID: 39430577 Free PMC article.
• Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up.

  Choe HJ, Moon JH, Kim W, Koo BK, Cho NH. Choe HJ, et al. Metabolism. 2024 Apr;153:155800. doi: 10.1016/j.metabol.2024.155800. Epub 2024 Jan 22. Metabolism. 2024. PMID: 38266957
• Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies.

  Kokkorakis M, Muzurović E, Volčanšek Š, Chakhtoura M, Hill MA, Mikhailidis DP, Mantzoros CS. Kokkorakis M, et al. Pharmacol Rev. 2024 May 2;76(3):454-499. doi: 10.1124/pharmrev.123.001087. Pharmacol Rev. 2024. PMID: 38697855 Review.
• Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?

  Staufer K, Stauber RE. Staufer K, et al. Biomedicines. 2023 Jul 26;11(8):2108. doi: 10.3390/biomedicines11082108. Biomedicines. 2023. PMID: 37626604 Free PMC article. Review.